Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · IEX Real-Time Price · USD
3.474
-0.076 (-2.14%)
Jul 22, 2024, 9:31 AM EDT - Market open
CELZ Employees
Creative Medical Technology Holdings had 4 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$2,250
Profits / Employee
-$1,319,049
Market Cap
4.68M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IM Cannabis | 95 |
| Biofrontera | 85 |
| Sharps Technology | 57 |
| Intelligent Bio Solutions | 51 |
| Processa Pharmaceuticals | 13 |
| Adial Pharmaceuticals | 7 |
| Artelo Biosciences | 6 |
CELZ News
- 12 days ago - Creative Medical Technology Holdings Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin - GlobeNewsWire
- 4 months ago - Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access - Business Wire
- 4 months ago - Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy - Business Wire
- 7 months ago - Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain - Accesswire
- 10 months ago - Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain - PRNewsWire
- 10 months ago - Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain - PRNewsWire
- 11 months ago - What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth? - Accesswire